Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947545900> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2947545900 abstract "e20682 Background: There is growing insight in the mechanisms underlying resistance to the 3 rd generation EGFR inhibitor osimertinib. Unlike resistance to 1 st generation inhibitors, these mechanisms not necessarily lead to sequential targeted therapy approaches. Here we report on the treatment of two patients with acquired resistance to osimertinib with a new detected BRAF V600E mutation as resistance mechanism. Methods: We identified two patients with EGFR-T790M-mutant advanced NSCLC with progression on osimertinib and detection of a new BRAFV600E mutation in a tumor rebiopsy by next-generation sequencing (NGS). No other known resistance mechanism beside T790M loss in one patient was found. Osimertinib was discontinued and BRAF-targeted combination therapy with dabrafenib and trametinib at standard dose was initiated. We monitored the clinical course with sequential 18 F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) / computed tomography (CT) assessing maximum standard uptake value (SUVmax), sequencing based liquid biopsies and tumor marker assessment. Results: Patient (1) with EGFR del19 (E746_A750del), preserved T790M mutation and acquired BRAF V600E mutation showed reduction in FDG uptake of 18% after 2 weeks of dabrafenib/trametinib that demonstrated a slight increase of 12% in a FDG-PET/CT scan 4 weeks thereafter and combination treatment has been continued. Patient (2) with EGFR del19 (E746_A750del), T790M loss and new BRAF V600E mutation showed continuous metabolic (+8% and + 39%, respectively) and morphologic progression after 2 and 4 weeks of dabrafenib and trametinib. A tumor rebiopsy showed no additional molecular changes. We changed the treatment to osimertinib and dabrafenib combination and observed an impressive metabolic response (-33%) after 2 weeks by FDG-PET/CT. Conclusions: BRAF V600E mutation has recently been described as a novel molecular resistance mechanism in osimertinib-resistant EGFR-mutant NSCLC. We describe one patient where combined BRAF/MEK inhibition with no additional EGFR-inhibition resulted in a preliminary feasible tumor control, but confirmatory CT staging is pending. In a second patient, co-inhibition of EGFR and BRAF pathway with osimertinib and dabrafenib was needed to overcome BRAF-mediated osimertinib resistance resulting in an impressive early tumor response that was not observed to either single-target inhibition of EGFR or BRAF. FDG-PET/CT was able to monitor tumor dynamics. Updated data will be presented." @default.
- W2947545900 created "2019-06-07" @default.
- W2947545900 creator A5000668683 @default.
- W2947545900 creator A5003606461 @default.
- W2947545900 creator A5006712577 @default.
- W2947545900 creator A5014839908 @default.
- W2947545900 creator A5017328208 @default.
- W2947545900 creator A5037915780 @default.
- W2947545900 creator A5047435894 @default.
- W2947545900 creator A5053252307 @default.
- W2947545900 creator A5056649824 @default.
- W2947545900 creator A5056803492 @default.
- W2947545900 creator A5058243253 @default.
- W2947545900 creator A5079134234 @default.
- W2947545900 creator A5080059818 @default.
- W2947545900 creator A5087050668 @default.
- W2947545900 creator A5088140147 @default.
- W2947545900 date "2019-05-20" @default.
- W2947545900 modified "2023-10-18" @default.
- W2947545900 title "Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation." @default.
- W2947545900 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e20682" @default.
- W2947545900 hasPublicationYear "2019" @default.
- W2947545900 type Work @default.
- W2947545900 sameAs 2947545900 @default.
- W2947545900 citedByCount "2" @default.
- W2947545900 countsByYear W29475459002020 @default.
- W2947545900 countsByYear W29475459002021 @default.
- W2947545900 crossrefType "journal-article" @default.
- W2947545900 hasAuthorship W2947545900A5000668683 @default.
- W2947545900 hasAuthorship W2947545900A5003606461 @default.
- W2947545900 hasAuthorship W2947545900A5006712577 @default.
- W2947545900 hasAuthorship W2947545900A5014839908 @default.
- W2947545900 hasAuthorship W2947545900A5017328208 @default.
- W2947545900 hasAuthorship W2947545900A5037915780 @default.
- W2947545900 hasAuthorship W2947545900A5047435894 @default.
- W2947545900 hasAuthorship W2947545900A5053252307 @default.
- W2947545900 hasAuthorship W2947545900A5056649824 @default.
- W2947545900 hasAuthorship W2947545900A5056803492 @default.
- W2947545900 hasAuthorship W2947545900A5058243253 @default.
- W2947545900 hasAuthorship W2947545900A5079134234 @default.
- W2947545900 hasAuthorship W2947545900A5080059818 @default.
- W2947545900 hasAuthorship W2947545900A5087050668 @default.
- W2947545900 hasAuthorship W2947545900A5088140147 @default.
- W2947545900 hasConcept C104317684 @default.
- W2947545900 hasConcept C121608353 @default.
- W2947545900 hasConcept C126322002 @default.
- W2947545900 hasConcept C143065580 @default.
- W2947545900 hasConcept C143998085 @default.
- W2947545900 hasConcept C2776256026 @default.
- W2947545900 hasConcept C2777626846 @default.
- W2947545900 hasConcept C2778087573 @default.
- W2947545900 hasConcept C2779438470 @default.
- W2947545900 hasConcept C2994294914 @default.
- W2947545900 hasConcept C501734568 @default.
- W2947545900 hasConcept C502942594 @default.
- W2947545900 hasConcept C54355233 @default.
- W2947545900 hasConcept C71924100 @default.
- W2947545900 hasConcept C86803240 @default.
- W2947545900 hasConceptScore W2947545900C104317684 @default.
- W2947545900 hasConceptScore W2947545900C121608353 @default.
- W2947545900 hasConceptScore W2947545900C126322002 @default.
- W2947545900 hasConceptScore W2947545900C143065580 @default.
- W2947545900 hasConceptScore W2947545900C143998085 @default.
- W2947545900 hasConceptScore W2947545900C2776256026 @default.
- W2947545900 hasConceptScore W2947545900C2777626846 @default.
- W2947545900 hasConceptScore W2947545900C2778087573 @default.
- W2947545900 hasConceptScore W2947545900C2779438470 @default.
- W2947545900 hasConceptScore W2947545900C2994294914 @default.
- W2947545900 hasConceptScore W2947545900C501734568 @default.
- W2947545900 hasConceptScore W2947545900C502942594 @default.
- W2947545900 hasConceptScore W2947545900C54355233 @default.
- W2947545900 hasConceptScore W2947545900C71924100 @default.
- W2947545900 hasConceptScore W2947545900C86803240 @default.
- W2947545900 hasLocation W29475459001 @default.
- W2947545900 hasOpenAccess W2947545900 @default.
- W2947545900 hasPrimaryLocation W29475459001 @default.
- W2947545900 hasRelatedWork W166857944 @default.
- W2947545900 hasRelatedWork W2075062823 @default.
- W2947545900 hasRelatedWork W2097699101 @default.
- W2947545900 hasRelatedWork W2295198861 @default.
- W2947545900 hasRelatedWork W2371438492 @default.
- W2947545900 hasRelatedWork W2398781322 @default.
- W2947545900 hasRelatedWork W2611702679 @default.
- W2947545900 hasRelatedWork W2613711128 @default.
- W2947545900 hasRelatedWork W2734336741 @default.
- W2947545900 hasRelatedWork W2770240948 @default.
- W2947545900 hasRelatedWork W2891706791 @default.
- W2947545900 hasRelatedWork W2906290888 @default.
- W2947545900 hasRelatedWork W2936807925 @default.
- W2947545900 hasRelatedWork W2979903352 @default.
- W2947545900 hasRelatedWork W3016888440 @default.
- W2947545900 hasRelatedWork W3127006122 @default.
- W2947545900 hasRelatedWork W3170835126 @default.
- W2947545900 hasRelatedWork W3185869221 @default.
- W2947545900 hasRelatedWork W3200033087 @default.
- W2947545900 hasRelatedWork W3212594364 @default.
- W2947545900 isParatext "false" @default.
- W2947545900 isRetracted "false" @default.
- W2947545900 magId "2947545900" @default.
- W2947545900 workType "article" @default.